摘要
目的探讨sST2在心力衰竭中的临床应用,为心力衰竭评估提供新的参考依据。方法选取湖南省人民医院2015年1-12月确诊为心力衰竭的患者50例作为实验组、非心衰的其他心血管疾病患者34例作为疾病对照组和健康体检者44例作为健康对照组。采集三组人员的静脉血检测sST2和NT-pro BNP。收集实验组的临床资料,分析sST2含量与心衰患者的联系,同时比较该指标与NT-pro BNP对心衰的临床诊断价值。结果实验组sST2均值为(48.43±10.21)ng/ml、疾病对照组为(24.69±9.35)ng/ml、健康对照组为(19.91±8.76)ng/ml,这三组sST2的均值经统计学处理其差异均有统计学意义(P<0.05);慢性和急性心衰患者的sST2均值分别为(61.43±12.45)和(35.41±12.23)ng/ml,两者差异有统计学意义(P<0.05);NYHA分级中Ⅱ级、Ⅲ级和Ⅳ级心衰患者的sST2均值分别为(29.42±12.33)、(36.19±10.42)和(66.40±13.44)ng/ml,差异均有统计学意义(P<0.05);sST2均值在心衰患者不同年龄和病因中差异无统计学意义(P>0.05);sST2和NT-pro BNP用于区分心衰和对照个体的ROC曲线下面积分别为0.753(95%CI:0.630~0.877,P<0.01)和0.848(95%CI:0.763~0.934,P<0.01)。结论 sST2作为一种新的血清标志物,在慢性心衰中显著升高,并与心衰严重程度相关,可与NT-pro BNP检测联合应用,有利于对心衰疾病作出正确诊断。
Objective To explore the clinical application of soluble ST2 （sST2） in heart failure （HF） so as to provide a new basis for the clinical assessment of HF. Methods Fifty patients diagnosed with HF in the People’s Hospital of Hunan Province from January to December 2015 were selected as the experimental group, 34 cardiovascular disease patients without HF as the disease control group, and 44 health examinees as the healthy control group. Venous blood samples of the three groups were collected, and the levels of sST2 and NT-proBNP were detected. Clinical data of the experimental group were collected. The relationship between sST2 and HF was analyzed, and then the clinical value of sST2 and NT-proBNP in diagnosis of HF was compared. Results The average levels of sST2 in the experimental group, the disease control group and the healthy control group were（48.43±10.21）ng/ml, （24.69±9.35）ng/ml and（19.91±8.76） ng/ml respectively, and the differences were statistically significant （P〈0.05）. The average levels of sST2 in chronic and acute HF subgroups were（61.43±12.45）ng/ml and（35.41±12.23）ng/ml respectively, with a statistically significant difference （P〈0.05）. The average levels of sST2 in NYHA II, NYHA III and NYHA IV subgroups were （29.42±12.33）ng/ml,（36.19±10.42）ng/ml and（66.40±13.44）ng/ml respectively, with statistically significant differences （all P〈0.05）. No statistically significant differences were found in the average levels of sST2 among groups with different ages and pathogeny （P〉0.05）. The areas under the ROC curve of sST2 and NT-proBNP for distinguishing between HF and all control individuals were 0.753 （95%CI：0.630-0.877, P〈0.01） and 0.848 （95%CI：0.763-0.934, P〈0.01） respectively. Conclusions As a new serum marker, the level of sST2 is significantly increased in chronic HF, and correlated with the severity of HF. Combined detection of sST2 and NT-proBNP is conducive to correct diagnosis of HF.
出处
《实用预防医学》
CAS
2017年第3期361-364,共4页
Practical Preventive Medicine
基金
湖南省卫生厅科研项目(C2013-065)
